Curriculum Vitae et Studiorum

INFORMAZIONI PERSONALI

Simona Valleggi

ESPERIENZE DI LAVORO

Da Febbraio 2015 ad oggi:

Clinical Trial Study Coordinator nel gruppo del Dr. Antonio Chella.

Dipartimento Cardiotoracico, UO Pneumologia Universitaria, DH Oncologico dell'Azienda Ospedaliero Universitaria Pisana. AOUP Cisanello; Pisa Italia.

Ottobre 2013-Febbraio 2015:

Assegnista di Ricerca nel gruppo del Prof. Ugo Valbusa.

Dipartimento di Fisica dell'Università di Genova. Genova; Italia.

Titolo del Progetto: Polymeric Nano-pores and Nano-channels as Bio-Molecular Sensors (NANOMAX project).

Settore Scientifico: FIS/07 Fisica Applicata (a Beni Culturali, Ambientali, Biologia e Medicina).

Aprile 2012-Aprile 2013

Assegnista di Ricerca nel gruppo del Dott. Vincenzo Lionetti.

Istituto di Scienze della Vita della Scuola Superiore Sant'Anna

Sezione di Fisiologia Clinica Consiglio Nazionale delle Ricerche (CNR). Pisa; Italia. *Titolo del Titolo del Progetto*: Multipotent Adipose Derived Adult Stem Cell for cardiovascular regeneration.

Settore Scientifico: BIO/09 Fisiologia.

Maggio 2010-Aprile 2012

Post-Doctoral fellowship nel gruppo del Prof. Nandita DeSouza e Dr. Jeff Bamber. Department of Physics of The Institute Of Cancer Research and MRI Unit of The Royal Marsden NHS Trust; Sutton, Surrey, UK.

Titolo del Progetto: Development and validation of new methodologies for imaging apoptosis using a multimodality approach in *in vitro* and *in vivo models*.

Settembre - Dicembre 2009

Post-Doctoral Position nel gruppo del Prof. Ishwarlal. Jialal.

Department of Pathology & Laboratory Medicine, University of California Davis Medical Centre (UCDMC), Sacramento, California.

Titolo del Progetto: Investigate the Role of C-Reactive Protein in a cardiovascular and metabolic disease setting in *in vitro* and *in vivo models*.

Marzo - Agosto 2009

Borsa di studio nel gruppo Dr. Marco Rossi.

Dipartimento di Medicina Interna, Azienda Ospedaliero Universitaria Pisana, Pisa, Italia.

Titolo del Progetto: Laser-Doppler Flowmetry peripheral microcirculation investigation in bariatric patients.

EDUCAZIONE

Gennaio-Dicembre 2013

Master di II Livello in Sperimentazione Clinica dei Farmaci

Titolo Tesi: *"Ethic and Statistic in Clinical Trials".*

Farmacologia Clinica. Dipartimento di Medicina Clinica e Sperimentale Scuola Medica. Università di Pisa. Pisa; Italia.

Marzo-Giugno 2013

Corso di Nutrizionista: Nutrizione basi e fondamenti.

A.C.S.I.A.N.: Associazione Centro Studi delle Intolleranze Alimentari e della Nutrizione, Pisa; Italia.

11Gennaio 2005-17Aprile 2008

Dottorato in Oncolgia Molecolare e Sperimentale

Titolo Tesi: *"Xenon induced gene expression analysis in animal models".*

Supervisore: Dr. AO. Cavazzana, M.D.

Scuola di Dottorato in Biomolecular Sciences (BIOS). Pisa; Italia.

Sezione di Patologia Molecolare, Azienda Ospedaliero Universitaria Pisana. Pisa; Italia.

Sessione 1-2004 **Abilitazione alla professione di Biologo** University of Pisa; Pisa, Italy

26 Ottobre 1995-11 Marzo 2004

Degree in Biological Sciences

Votazione 110/110 cum Laude

Titolo Tesi: *"Identification of differentially expressed genes induced in rat brain by Acetyl-L-Carnitine."*

Supervisore: Prof. Marcello Brunelli, Dr. Giovanna Traina.

Dipartimento di Fisiologia, Università di Pisa. Pisa; Italy.

LINGUE STRANIERE

Italiano: Madre Lingua

Inglese: Ottima Conoscenza scritta e parlata

Francese: Scolastico

CAPACITA' COMUNICATIVE

Eccellenti capacità di comunicazione, sia scritte che verbali.

Ampia esperienza nel parlare e fare presentazioni a audience sia scientifiche che non, sia nazionali che internazionali.

Esperienza in training e insegnamento.

CAPACITA' ORGANIZZATIVE

Eccellente capacità organizzativa e assoluto rispetto delle priorità.

CONOSCENZA IT

Ottima conoscenza di Office: Word, Excel, Power Point, Outlook & Internet Explorer, sia in ambiente Windows che Macintosh.

Ottima conoscenza di software lavoro-specifici.

ESPERIENZA in CLINICAL TRIALs

- A Phase II Trial of Pemetrexed and cisplatin or carboplatin in combination with NovoTTF Therapy as First-line Treatment in Malignant Pleural Mesothelioma. Code: EF-23. NOVOCURE

- A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer. CLDK378A2301. Novartis

- A phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib. CLDK378A2303. Novartis

- A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non–Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent. Incyte266. Incyte

- A Phase III, open-label, multicentre, randomized study to investigate the efficacy and the efficacy and safety of MPDL3280A (Anti-PD-L1 Antibody) compared to Docetaxel in patients with non-small cell lung cancer after failure with platinum containing chemotherapy. G028915/0AK. Roche

- A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-centre, International Study of MEDI4736, as Sequential Therapy in Patients with Locally Advanced Unresectable Non-Small Cell Lung Cancer (Stage III) who have not Progressed following Definitive, Platinum-based, Concurrent Chemoradiation therapy. (PACIFIC) D4191C00001. Astra Zeneca

- A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen (ATLANTIC). D4191C00003. Astra Zeneca

- Crizotinib in pre-treated metastatic non-small-cell lung cancer with MET amplification or ROS1 translocation (METROS). Fondazione Ricerca Traslazionale (FoRT)

- A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult patients with cMet positive non-small cell lung cancer (CEGF816X2201C). Novartis

- Compassionate use of Nintedanib (BIBF 1120) in association with Docetaxel (BI 1199.55/NPU) in advanced or metastatic NSCLC patient. Boehringer-Ingelheim.

- Randomized, multicenter, phase III, open-label study of Alectinib versus chemotherapy in anaplastic lymphoma kinase positive advanced non-small cell lung cancer patients previously treated with chemotherapy and crizotinib. M029750. Roche.

- A Phase III, Open label, Randomised, Multi-centre, International Study of MEDI4736, versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at

Least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC). D4191C00004. Astra Zeneca

- Compassionate use of oral LDK378/Ceritinib in advanced or metastatic NSCLC patient with ALK translocation. CLDK378A2401. Novartis.

- Compassionate use of Nivolumab in squamous and non squamous advanced or metastatic NSCLC patient. BMS-936558. Bristol Meyer Squibb.

- Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy with an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI).ASTRIS. D5160C00022. Astra Zeneca

- A multicenter, randomized, double-blind Phase III trial to evaluate efficacy and safety of BI 695502 plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous Non-Small Cell Lung Cancer. 1302.5. Boehringer-Ingelheim.

- A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma. MORAb-009-201. Morphotek

- Compassionate use of Alectinib in anaplastic lymphoma kinase positive advanced non-small cell lung cancer pretreated with Crizotinib. ROCHE CU ML40066.

- Compassionate use of BRIGATINIB (AP26113) in anaplastic lymphoma kinase positive advanced non-small cell lung cancer. Takeda

- A randomized parallel group phase III trial of OSE 2101 as 2nd line after prior platinumbased chemotherapy failure or as 3rd line after platinum-failure and checkpoint inhibitorfailure, compared with standard treatment (docetaxel or pemetrexed) in HLA-A2 positive patients with locally advanced (IIIB) unsuitable for radiotherapy or metastatic Non-Small-Cell Lung Cancer. (OSE2101C301).OSE Pharma.

- A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI–PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB–IIIA NON–SMALL CELL LUNG CANCE. G029527 Roche.

- A PHASE I/III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARBOPLATIN PLUS ETOPOSIDE WITH OR WITHOUT ATEZOLIZUMAB (ANTI–PD-L1 ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER. G030081 Roche.

- Compassionate use of DURVALUMAB (MEDI4736) in Stage III Non–Small-Cell Lung Cancer after Chemoradiotherapy. AstraZeneca

- A PHASE III/IV, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) TO INVESTIGATE LONG-TERM SAFETY AND EFFICACY IN PREVIOUSLY-TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (TAIL). M039171 Roche

- Lorlatinib (PF-06463922) Compassionate Use. Pfizer

- Treatment Patterns among Patients with Advanced Small Cell Lung Cancer (SCLC) in Europe. Observational Study Protocol CA209913. BMS

Conoscenze Bio-Molecolari

- Colture e Co-Culture cellulari
- Estrazione e analisi di RNA, DNA e proteine
- RNA interference
- Isolamento e analisi di Esosomi
- Tecniche di elettroforesi (Southern, Northern and Western blots)
- Flow cytometry
- Manipolazione e analisi di campioni sangue
- ELISA
- Polymerase Chain Reaction (PCR) and Reverse-Transcription Polymerase Chain Reaction (relative RT-PCR)
- Suppression Subtractive Hybridization
- Tecniche di Clonazione
- Fissazione e perfusione tessuti (paraformaldeide)
- Immuno-citochimica & Immuno-istochimica
- Analisi sequenze *In silico*
- Analisi statistica di immagini biologiche
- Litografia soft(PDMS); fabbricazione device polimerici micro e nano strutturati
- Bio-Funzionalizzazione di superfici di silicio e PDMS
- Microscopia ottica e a fluorescenza
- Manipolazione e trattamento animali da laboratorio, Xenograft inclusi.. **Animal (Scientific Procedures) Act 1986.** CBS Imperial College, London UK. Personal Licence to carry out regulated procedures on living animals under the ANIMAL (Scientific Procedures) ACT 1986; (certificate IMP/10/152, 9th July 2010; PIL 70/23103).

Pubblicazioni

* Traina G, **Valleggi S**, Bernardi R, Rizzo M, Calvani M, Nicolai R, Mosconi L, Durante M and Brunelli M. IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES INDUCED IN THE RAT BRAIN BY ACETYL-L-CARNITINE AS EVIDENCED BY SUPPRESSION SUBTRACTIVE HYBRIDISATION. Brain Res Mol Brain Res. 2004 Dec ; 132(1):57-63.
* Cattano D, **Valleggi S**, Ma D, Kastsiuchenka O, Abramo A, Sun P, Cavazzana AO, Natale G, Maze M and Giunta F. XENON INDUCES TRANSCRIPTION OF ADNP IN NEONATAL RAT BRAIN. Neurosci Lett. 2008 Aug ; 440(3): 217-21.
* **Valleggi S**, Cavazzana AO, Bernardi R, Ma D, Natale G, Maze M, Cattano D and Giunta F. XENON UP-REGULATES SEVERAL GENES THAT ARE NOT UP-REGULATED BY NITROUS OXIDE. J Neurosurg Anesthesiol. 2008 Oct; 20(4):226-32.
* Devaraj S, **Valleggi S**, Siegel D and Jialal I. ROLE OF C-REACTIVE PROTEIN IN CONTRIBUTING TO INCREASED CARDIOVASCULAR RISK IN METABOLIC SYNDROME. Curr Atheroscler Rep. 2010 Mar; 12(2):110-8.
* Cattano D, **Valleggi S**, Abramo A, Forfori F, Maze M and Giunta F. NITROUS OXIDE DISCRETELY UP-REGULATES NNOS AND P53 IN NEONATAL RAT BRAIN. Minerva Anestesiol. 2010 Jun; 76(6):420-4.
* **Valleggi S**, Devaraj S, Dasu MR and Jialal I. C-REACTIVE PROTEIN ADVERSELY ALTERS THE PROTEIN-PROTEIN INTERACTION OF THE ENDOTHELIAL ISOFORM OF NITRIC OXIDE SYNTHASE. Clin Chem. 2010 Aug; 56(8):1345-8.
* Cattano D, **Valleggi S**, Cavazzana AO, Patel CB, Ma D, Maze M, Giunta F. XENON EXPOSURE IN THE NEONATAL RAT BRAIN: EFFECTS ON GENES THAT REGULATE APOPTOSIS. Minerva Anestesiol. 2011 Jun;77(6):571-8. PubMed PMID: 21617619
* **Valleggi S**, Patel CB, Cavazzana AO, Ma D, Giunta F, and Cattano D. XENON UPREGULATES HYPOXIA INDUCIBLE FACTOR 1 ALPHA IN NEONATAL RAT BRAIN UNDER NORMOXIC CONDITIONS. Research Article 510297 ISRN Anesthesiology 2011.
* **S Valleggi**, H Parkes, MI Walton, N Bush, MD Garrett, N DeSouza and J Bamber. TIMING APOPTOSIS: A MULTIMODALITY IMAGING APPROACH TO CASPASE 3. 2011 World Molecular Imaging Conference. September 7-10; San Diego, CA. Abstract # 1123971.

In fede

Pisa,

Dr. Simona Valleggi, PhD

Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae in base art. 13 del D. Lgs. 196/2003